This is the authors' abstract. We don't add key points for this paper.
Assessment of Different Neoplasias in the Adnexa (ADNEX) is the best-performing model to estimate the risk of malignancy in ovarian tumors. We assessed the incremental value of serum proteins over ADNEX predictors in an exploratory multicenter study. In a cohort of 932 patients with an adnexal mass scheduled for surgery, 33 serum proteins were preoperatively quantified using multiplex high-throughput and electrochemiluminescence immunoassays. Using multivariable logistic regression, ADNEX predictors alone had an area under the receiver operating characteristic curve (AUC) of 0.91 (95% confidence interval, 0.89-0.93) to discriminate benign from malignant tumors. This AUC increased most after adding HE4 (+0.03) or CA125 (+0.02). CA72.4 increased AUCs to discriminate secondary metastatic tumors from benign (+0.03), borderline (+0.03), and stage I tumors (+0.03). CA15.3 increased AUCs to discriminate borderline tumors from stage I (+0.01) and stage II-IV tumors (+0.03). While CA125 and HE4 had the highest added value over ADNEX predictors, CA72.4 and CA15.3 may improve discrimination between malignant subtypes.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Coosemans et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: